ArticleVaccines2026

A Reanalysis of the FDA's Benefit-Risk Assessment of Moderna's mRNA-1273 COVID Vaccine Based on a Model Incorporating Benefits Derived from Prior COVID Infection.

Paul S Bourdon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.